Cognizant Technology Solutions
Will shares go even higher? Here are three reasons why they likely will.
1. Cognizant has shown that it can weather tough economic times relatively well.
Some investors might have seen weak forecasts from Indian outsourcing firm Infosys
Global technology consulting and outsourcing firm Accenture
For one thing, Cognizant receives nearly 80% of its revenue from North America, which has fared better economically than Europe so far in 2012. By comparison, North America accounts for 64% of Infosys' total revenue. Accenture receives 45% of its revenues from the Americas region.
Cognizant also benefits from tight relationships with several larger customers. Around 25% of revenue is generated from the company's top 10 customers. These relationships help provide a steady financial base for the company as it seeks other growth opportunities.
2. Cognizant's current weaknesses could become strengths over the long run.
While Cognizant's strong North American presence certainly helps when other parts of the world are struggling, it also represents a weakness. However, the company is making strides to increase its international client base.
CEO Francisco D'Souza points to Brazil as a good example. During the company's earnings call, D'Souza noted that Cognizant won several new clients in Brazil after establishing a strong local leadership team and building out a local delivery center.
Despite current issues in Europe, Cognizant says that the region remains an attractive market over the long run. The company is focusing on expanding its capabilities, especially in France and Germany. Cognizant management reports that it has a good pipeline of prospective clients in Europe, which could set the company up to perform well in the region in 2013.
Another current weak area for the company is in the health-care market. Health care makes up around 27% of total revenue. The health-care segment grew more slowly earlier this year as pharmaceutical companies spent less because of drugs going off patent. However, Cognizant regained sequential growth in the segment in the second quarter.
Cognizant expects only modest growth in the health-care segment for the near term. However, potential longer term drivers include resurgence in pharmaceutical industry spending as new drugs come to market and increased technology spending by health plans as they implement more provisions of the Accountable Care Act.
3. Cognizant has a good window for seeing how the rest of 2012 will unfold.
Probably the most important reason for expecting that Cognizant shares will continue to increase is that the company has a pretty clear picture for how the rest of the year will unfold. With that knowledge, management reaffirmed revenue guidance for the year and raised its adjusted profit forecast.
Two recent deals bolster Cognizant's optimism. In June, the company announced a $330 million expansion in its relationship with the U.S. retirement, investment management and insurance operations of Dutch-based ING
Cognizant was also recently selected by Royal Philips Electronics
High-profile projects such as these can reinforce other organizations' perception of Cognizant as a leader in the technology-enabled business transformation arena. That could help the company win even more business in the future.
Despite the overall dismal picture globally, Cognizant appears to be in good shape to continue its remarkable growth. One area of concern, though, is currency fluctuations. Cognizant absorbed currency exchange losses totaling more than $20 million. However, the company expects its overall business growth to mitigate these losses.
Cognizant's forward P/E of 16.42 is closer to the low end of its five-year range than to the high end. Even with the surge after the earnings announcement, shares still trade 20% off the highs from earlier this year. It seems likely that Cognizant will regain those highs in the coming months.
While Cognizant and others help companies adjust to changing technology, there is a technology transformation under way that will interest growth investors. To learn about this major change, check out The Motley Fool's special report "The Next Trillion-Dollar Revolution." Get your free copy now!
Fool contributor Keith Speights owns no shares in the stocks mentioned above. Motley Fool newsletter services have recommended buying shares of Accenture. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.